Another recent study, 344 which examined the impacts of another GLP-1, GIP and GCGR tri-agonist in rodents, found that treatment with this agonist decreased body weight, food intake and hyperglycaemia
And if youre curious about microdosingAKA starting with the lowest effective dose to cut side effects and coststhese platforms make the process especially straightforward
In other words, barely 1 in 7 patients remains on GLP-1 therapy after two years , despite obesity being a chronic condition requiring long-term treatment
PubMed, de Graaf, Chris, et al
Once activated, several beneficial processes begin: Appetite signals to the brain increase: GLP-1 communicates with appetite centers in the brain, particularly areas involved in satiety regulation